Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Sep;25(5):347-357.
doi: 10.1097/PRA.0000000000000415.

Personality as a Predictor of Treatment Response to Escitalopram in Adults With Body Dysmorphic Disorder

Angela Fang, Rachel Porth, Katharine A Phillips, Sabine Wilhelm
Randomized Controlled Trial

Personality as a Predictor of Treatment Response to Escitalopram in Adults With Body Dysmorphic Disorder

Angela Fang et al. J Psychiatr Pract. 2019 Sep.

Abstract

Objective: Serotonin reuptake inhibitors (SRIs) are the first-line pharmacotherapy for body dysmorphic disorder (BDD), a common and severe disorder. However, predictors and correlates of treatment response are not well understood. A closer examination of baseline personality dimensions and disorders and of changes in personality during SRI treatment is needed to advance knowledge of this clinically important issue.

Method: We conducted a secondary analysis of data from a pharmacotherapy relapse prevention trial of the SRI escitalopram in adults with BDD to examine personality dimensions and traits, as well as whether these variables predict and correlate with treatment response. A total of 65 participants with BDD completed the Revised NEO Personality Inventory (NEO PI-R) before starting open-label treatment with escitalopram and 42 participants completed the NEO PI-R after treatment.

Results: At baseline, participants with BDD displayed higher levels of neuroticism and lower levels of extraversion than a normed reference group. Higher baseline neuroticism was a significant predictor of nonresponse to escitalopram treatment, even when baseline depression severity was controlled for. Changes in neuroticism were not associated with treatment response.

Conclusion: Our findings underscore the relationship between BDD and neuroticism, and they suggest a link between neuroticism and SRI treatment response.

Trial registration: ClinicalTrials.gov NCT00149799.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Phillips KA, Menard W, Fay C, et al. Demographic characteristics, phenomenology, comorbidity, and family history in 200 individuals with BDD. Psychosomatics. 2005;46:317–325. - PMC - PubMed
    1. Phillips KA, Menard W. Suicidality in body dysmorphic disorder: a prospective study. Am J Psychiatry. 2006;163:1280–1282. - PMC - PubMed
    1. Digman JM. Personality structure: emergence of the five-factor model. Annu Rev Psychol. 1990;41:417–440.
    1. Costa PT, McCrae RR. Revised NEO Personality Inventory (NEO PI-R) and NEO Five-Factor Inventory (FFI) Professional Manual. Lutz, Florida: Psychological Assessment Resources;1992.
    1. Clark LA. Assessment and diagnosis of personality disorder: perennial issues and an emerging reconceptualization. Annu Rev Psychol. 2007;58:227–257. - PubMed

Publication types

MeSH terms

Associated data